A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours
一项 I 期、开放标签、多中心、首次人体试验，旨在评估 PD-1 抑制剂 AMG 404 在晚期实体瘤患者中的安全性、药代动力学和疗效。
期刊:BMJ Open
影响因子:2.3
doi:10.1136/bmjopen-2024-088578
Price, Timothy; Lugowska, Iwona; Chawla, Sant P; Falchook, Gerald; Subbiah, Vivek; Monzon, Jose G; Arkenau, Hendrik-Tobias; Hui, Mun; Kuboki, Yasutoshi; Dziadziuszko, Rafal; Shibaki, Ryota; Hong, Min Hee; Tan, Daniel; Rocha Lima, Caio Max; Wang, Kejia; Hindoyan, Antreas; Shi, Weibing; Wong, Hansen; Kistler, Mira; Prenen, Hans
